Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2021

View Archived Issues

Blueprint Medicines to acquire LNG-451 with Lengo Therapeutics acquisition

Oncostatin M targeting as approach for treating inflammatory pruritus

Metabotropic glutamate mGlu2 receptor found to be associated with alcoholism

IBI-319, a novel CD137/PD-1 bispecific antibody with limited systemic toxicity

Shanghai Longwood Biopharmaceuticals divulges PD-1/PD-L1 interaction inhibitors

Dartmouth College discloses new GR antagonists

Txinno Bioscience presents new ENPP1 inhibitors

Eli Lilly and Company identifies CSF1R inhibitors

New RIPK1 inhibitors presented by National Institute of Pharmaceutical R&D

B-cell targeting controls chronic viral infections in mice

New transgenic hACE2-expressing mouse model shows efficacy of vaccine against brain COVID-19

Discovery of novel antifungal compounds with improved metabolic stability

PNV-2 reduces metastases in animal model of triple-negative breast cancer

Scorpion Therapeutics unveils lead programs in cancer

Polyphenylene carboxymethylene shows anti-SARS-CoV-2 activity in vitro

Janssen publishes PK/PD data for the anticoagulant-reversing agent JNJ-67842125

Indomethacin-based PROTACs show pan-coronavirus activity, including SARS-CoV-2 strains

NHD2 is essential in Leishmania independently of complex I, emerging as a potential drug target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...